Profound but transient changes in the inflammatory milieu of the blood during autologous hematopoietic stem cell transplantation

Autologous hematopoietic stem cell transplantation (AHSCT) is a well-proven treatment used predominantly for blood malignancies, but also for solid tumors and inflammatory diseases such as multiple sclerosis (MS) and systemic sclerosis [1 –3]. While the removal of malignant cells is assumed to be key in the treatment of lymphomas and myelomas, less is known about the mechanisms behind the improvements of patients with inflammatory diseases. In order to minimize the mortality and morbidity related to the conditioning regimens [4–6 ], non-myeloablative conditioning regimens are now preferred for MS [7].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research